Navigation Links
Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection

e ANA975 IND, or that the clinical development of ANA975 will be able to be resumed. There also is no guarantee regarding Anadys' future involvement with, or value recognition from, the ANA380 program. Anadys' results may be further affected by risks related to its collaborative relationships with Novartis and LG Life Sciences, competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to successfully develop and market products, the level of effort that its collaborative partners devote to development and commercialization of its product candidates, difficulties or delays in its pre-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments involving future products and its ability to obtain additional funding to support its operations. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2006 and the "Risk Factors" section of Anadys' Form 10-Q for the quarter ended March 31, 2007. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

CONTACT: Vince Reardon, Sr. Director, Investor Relations & CorporateCommunications of Anadys Pharmaceuticals, Inc., +1-858-530-3653, vreardon@anadyspharma.com

Web site: http://www.anadyspharma.com/

Ticker Symbol: (NASDAQ-NMS:ANDS)

Terms and conditions of use apply
Copyright © 2007 PR Newswi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor Activity of Natural Killer Cells
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:2/27/2015)... Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ROTH Conference on Tuesday, March 10, 2015. Rob ... , Chief Financial Officer, will present at 4:00 p.m. ... at the conference at the Ritz Carlton in ...
(Date:2/26/2015)... -- Finesse expands office in Leicester, United Kingdom ... of its operations in Leicester , ... for customers is expected shortly afterward. With ... the current office, the new premises will double the ... Finesse to bring on more service personnel. The new ...
(Date:2/26/2015)... , Feb. 26, 2015  Today the ... The psychological and physical side effects of pain ... opioid painkillers, such as Vicodin and Oxycontin, are safer ... Americans overdose on prescription painkillers than on heroin and ... and CEO of NSC. "Yet, these medications are marketed ...
Breaking Medicine Technology:Uroplasty to Participate in the 27th Annual ROTH Conference 2New Finesse Office in United Kingdom 2National Safety Council: Opioid prescription painkillers have hidden, deadly side effects 2
... NEW YORK, Oct. 1 Keryx Biopharmaceuticals,Inc. (Nasdaq: ... the,Company,s President, will present an overview of the Company,s ... Growth Stock,Conference in New York City. Dr. Henderson,s presentation ... ET. Dr. Henderson,s presentation will be webcast live ...
... -Two 48-week Superiority Studies versus Hepsera(R) in Patients with Chronic ... Hepatitis B-,-Studies will also Assess Clevudine,s ... ... Pharmasset, Inc.,(Nasdaq: VRUS ) has commenced dosing in Phase 3 registration clinical trials,of clevudine ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 2Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 3Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 4Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV 5
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 March—also ... good time to remind ourselves and others that ... say Atlantic NeuroSurgical Specialists (ANS). , Concussions are ... account for 75% of TBIs. There are 1.6-3.8 ... may sound benign, but it is a brain ...
(Date:2/28/2015)... 2015 A study out of the ... therapy procedure for the treatment of a hereditary ocular ... Authored by Dr. Robert MacLaren, professor of ophthalmology ... Lancet Medical Journal on January 16, 2014 , the ... genetic disorder that mostly affects men and leads to ...
(Date:2/28/2015)... February 28, 2015 National ... outsourced sales, marketing and supply chain management for ... Botanicals, is bringing its award winning solutions for ... Botanicals’ products are specifically created to combat thinning-damaged ... BIOTA is committed to marrying science with nature ...
(Date:2/28/2015)... AZ (PRWEB) February 28, 2015 Kaylie ... and alcohol treatment center , and current student obtaining ... University, has implemented a weekly forum in psychoeducation on ... school in Flagstaff, AZ as part of her studies. ... big need for support and counseling at the high ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... test the drug manufactured by German pharmaceutical company TeGenero by ... which was designed to treat rheumatoid arthritis, leukaemia and multiple ... six men who fell seriously ill after taking part in ... like his brain was on fire. Student Nav Modi, 24, ...
... suggests that thinking that you are strong and muscles are ... Hull University research team which asked 30 subjects to do ... focused on what the muscles were doing. ,The ... which monitored levels of electrical activity in their biceps and ...
... a news study it has been shown that babies who ... have the much feared consequences and is safe. The way ... theory was researched and assessed by unconnected Nottingham researchers to ... was pioneered by controversial Stoke-based paediatrician Professor David Southall. ...
... alcohol intake seems to question the earlier studies that ... drinkers, as compared to abstainers or heavy drinkers. ... mistake in the perception of who “abstainers” are, when ... PhD, emerita professor at the University of California, San ...
... 7-day old baby was charred to death due to a short ... their joy and hopes. The incubator in which the baby was ... incident had happened due to negligence of the hospital staff while ... were saved due to prompt action of the medical staff who ...
... to the tune of ?4m or more will be allocated ... spending should take care of containing// the unhealthy trend, atleast ... up by almost 50%. ,A senior medical post ... with suicidal tendencies, according to Mr Woodward. To enable this ...
Cached Medicine News:Health News:High Spirits :Second Thoughts on the Mini Pegs 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: